Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Japan’s Healthcare Spend Grows to 44.4 Trillion Yen in FY2019
November 10, 2021
- Govt Panel Urges Support for Domestic Development and Production of COVID-19 Vaccines, Drugs to Ensure Supply
November 10, 2021
- MOF Calls for Stepwise Cuts in 2% Adjustment Rate, Timeline towards Abolishment
November 9, 2021
- Japan Drug Spending Up 2.3% Annually Since 2000, Outstripping GDP Growth: MOF
November 9, 2021
- MHLW to Conduct Follow-Up Health Survey on COVID-19 Vaccinations
November 9, 2021
- MHLW Panel Tables Decision on Efient’s Preventive Use for ICD Recurrences; Lilly's Migraine Med, Jardiance's Heart Failure Indication OK'ed
November 9, 2021
- Chuikyo Split over 2% Adjustment Rate, Off-Year Re-Pricing; JPWA Says Wholesalers Are in Dire Straits
November 8, 2021
- Industry Pushes PMP Coverage for Additional Indications, Payers See This Need Too but Only for Certain Products: Chuikyo
November 8, 2021
- Chuikyo Calls for Combining Multiple Steps to Curb Spend for Potential Super Big Sellers Like Aducanumab, No Objection to Listing
November 8, 2021
- JGA Sees New Generics as Financial Resources Necessary to Increase Production Capacity: Chuikyo Hearing
November 8, 2021
- Japan Approves Ronapreve to Prevent Symptomatic COVID-19
November 5, 2021
- Herceptin’s Salivary Cancer Use Sails through PAFSC; Label Expansions for I/O Drugs, Lorbrena in Line for Approval
November 5, 2021
- Ronapreve Clears Key Panel for COVID-19 Prevention, SC Use
November 5, 2021
- Pfizer’s COVID-19 Booster Up for PAFSC Review on Nov. 10
November 5, 2021
- Booster Shots to Start with Pfizer Vaccine: MHLW
November 2, 2021
- G20 Ministers Vow to Boost Vaccine Supply to Developing Countries
November 2, 2021
- Noda, Tokashiki, More in LDP Healthcare Clique Lose Seats in Lower House Poll
November 1, 2021
- Japan Panel OKs Booster Shots for All People Who Took 2 Doses
October 29, 2021
- Late-Phase Trials with Overseas Participation Pragmatic Approach for Japan-Made COVID-19 Vaccine Development: PMDA Director
October 29, 2021
- Ronapreve Up for PAFSC Review for Preventive Use on Nov. 4
October 29, 2021
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…